Drugs / OTS167
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02926690 | May 2017 → Sep 2027 expected | triple-negative breast carcinoma | OncoTherapy Science, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT01910545 | Aug 2013 → Apr 2016 | cancer, metastatic neoplasm | OncoTherapy Science, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02795520 | Apr 2016 → May 2021 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | OncoTherapy Science, Inc. | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 9
All press releases naming this drug 19 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTS167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02795520 ↗ |
| Known as | MELK INHIBITOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL3688339 ↗ |
| Known as | OTSSP167 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3688339 ↗ |
| Action | Inhibit | “OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor” NCT01910545 ↗ |
| Modality | Small molecule | — CHEMBL3688339 ↗ |
| Route | Intravenous | “Pharmacological Study of Intravenous OTS167” NCT02795520 ↗ |
| Target | MELK | “OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor” NCT01910545 ↗ |